ViiV completes BMS HIV pipeline purchase
pharmafile | February 23, 2016 | News story | Manufacturing and Production, Medical Communications, Research and Development | Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV
ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets.
Originally announced in December, the deals, which could be worth as much almost $1.5 billion, included an upfront payment of $317 million, and development and first commercial sale milestones of up to $518 million for the late-stage assets.
The payments for the preclinical and discovery stage HIV research business are of $33 million upfront, followed by development and first commercial sales milestones of up to $587 million, and further consideration based on future sales performance.
The late-stage assets now in ViiV’s portfolio include fostemsavir (BMS-663068), an attachment inhibitor currently in phase III development for heavily treatment-experienced patients. Fostemsavir gained Breakthrough Therapy Designation from the FDA last year and is expected to be filed for regulatory approval in 2018. Other late stage assets acquired are the maturation inhibitor (BMS-955176), currently in phase IIb development for both treatment-naive and treatment experienced HIV patients, and a back-up maturation inhibitor candidate (BMS-986173).
Early-stage assets purchased as part of the deal include a novel biologic (BMS-986197) with a triple mechanism of action, an additional maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
Specialist HIV company ViiV was formed in 2009, and it is owned in a majority by GSK, with Pfizer and Japan’s Shionogi also owning stakes in the firm.
Commenting on the successful completion of the transaction, Dominique Limet, chief executive of ViiV Healthcare, says: “As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry. The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV.”
Joel Levy
Related Content
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase …
